Subcutaneous Decitabine
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelodysplastic Syndrome
Conditions
Myelodysplastic Syndrome
Trial Timeline
Oct 1, 2006 → Feb 1, 2009
NCT ID
NCT00282399About Subcutaneous Decitabine
Subcutaneous Decitabine is a phase 1 stage product being developed by Eisai for Myelodysplastic Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00282399. Target conditions include Myelodysplastic Syndrome.
What happened to similar drugs?
7 of 19 similar drugs in Myelodysplastic Syndrome were approved
Approved (7) Terminated (7) Active (7)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00282399 | Phase 1 | Terminated |
Competing Products
20 competing products in Myelodysplastic Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 23 |
| JSP191 | Jasper Therapeutics | Phase 1 | 11 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 15 |
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 14 |
| Erlotinib Hydrochloride | Astellas Pharma | Phase 2 | 35 |
| Decitabine + Decitabine + Decitabine | Eisai | Phase 2 | 35 |
| Decitabine + Valproic Acid | Eisai | Phase 2 | 35 |
| decitabine + decitabine | Eisai | Phase 2 | 35 |
| decitabine + azacitidine | Eisai | Approved | 35 |
| Decitabine | Eisai | Phase 2 | 27 |
| decitabine + decitabine + decitabine + decitabine | Eisai | Phase 1 | 29 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid | Eisai | Phase 2 | 35 |
| Decitabine | Eisai | Phase 2 | 35 |
| Galunisertib + Placebo | Eli Lilly | Phase 2/3 | 38 |
| DSP-7888 | Sumitomo Pharma | Phase 1/2 | 32 |
| TP-0184 | Sumitomo Pharma | Phase 1/2 | 24 |
| Decitabine | Johnson & Johnson | Phase 2 | 35 |
| Epoetin alfa | Johnson & Johnson | Phase 2 | 27 |
| ZARNESTRA, tipifarnib, R115777 | Johnson & Johnson | Phase 2 | 35 |
| Decitabine | Johnson & Johnson | Phase 2 | 27 |